Loading…
Japanese maker of medical devices and pharmaceutical packaging, including glass vials, syringes and dialysis products.
Japanese maker of medical devices and pharmaceutical packaging, including glass vials, syringes and dialysis products.
Sells disposable medical products that hospitals reorder, such as syringes, needles and dialysis products, alongside glass vials and pre-filled syringes sold to drug companies, where regulatory qualification locks in orders. It also makes generic medicines.
In one line: A diversified med-device/pharma-packaging maker like a smaller Becton Dickinson.
Moat: narrow (scale, regulatory licence, installed base). Broad regulated manufacturing footprint and long qualification cycles with pharma customers.
Headquarters: Osaka, Japan · Founded: 1954 · Employees: 38,593
Size NIPRO (8086.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.55B, the 562nd largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,390 on 6 Nov 2026.
Performance Over six months the shares fell 8.5%, against +8.0% for the median peer and +1.8% for the Japan market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 2.7% over the last twelve months (peer median +11.7%); the operating margin is 5.7% (peer median 15.3%).
Valuation It trades at 14.9× forward earnings against a peer median of 22.7× (3rd cheapest of 17).
Capital Return on invested capital runs 2.2 points below its cost of capital (5.0% WACC).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥669B | ¥661B | ¥645B | ¥587B | ¥545B |
| Revenue growth | — | +2% | +10% | +8% | — |
| Gross profit | ¥212B | ¥213B | ¥194B | ¥174B | ¥166B |
| EBITDA | ¥102B | ¥101B | ¥92.2B | ¥81.2B | ¥66.5B |
| Net income | ¥14.1B | ¥13.5B | ¥5.11B | ¥11.1B | ¥4.58B |
| Free cash flow | n/a | -¥7.67B | -¥8.15B | -¥21.3B | -¥74.7B |
| Capital expenditure | n/a | ¥62.3B | ¥76.6B | ¥94.3B | ¥85.1B |
| Total debt | ¥662B | ¥638B | ¥632B | ¥630B | ¥596B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| NIPRO 8086.T | $1.55B | -9% | +3% | 6% | 14.9× | n/a |
| Becton Dickinson BDX | $57.7B | +43% | -3% | 15% | 16.0× | 9.6% |
| Fresenius Medical Care FME.DE | $12.6B | +14% | 0% | 11% | 10.4× | -3.6% |
| Terumo 4543.T | $23.4B | +25% | +14% | 17% | 24.6× | 8.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 8086.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.3% | +3.2% | 11th highest of 21 |
| 6-month return | -8.5% | +8.0% | 6th lowest of 20 |
| Distance from 52-week high | -21.1% | -21.2% | 10th highest of 21 |
| Revenue growth (TTM) | +2.7% | +11.7% | 6th lowest of 21 |
| Operating margin | 5.7% | 15.3% | 8th lowest of 21 |
| Forward P/E | 14.9× | 22.7× | 3rd cheapest of 17 |
| ROIC minus cost of capital | -2.2 pp | +1.5 pp | 8th lowest of 21 |
| EV / EBITDA | 8.5× | 15.5× | 2nd cheapest of 11 |
| Net debt / EBITDA | 5.5× | -0.1× | 2nd most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 14.9× | n/a | n/a |
| NovoCure NVCR | United States | $1.55B | -26% | +13% | -17% | n/a | n/a | n/a |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 7.7× | 22.3% | -6.0% |
| CONMED CNMD | United States | $1.53B | +40% | +2% | 2% | 11.1× | 32.4% | +9.8% |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% | +18.3% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% | +23.4% |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 17.6× | -2.1% | +3.3% |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 27.6× | 22.0% | +22.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.63B | n/a | +35% | 17% | n/a | n/a | n/a |
| Beijing Balance Medical Technology 688198.SS | China | $1.47B | -26% | +10% | 28% | 46.6× | 22.6% | +27.6% |
| Rigaku 268A.T | Japan | $1.66B | -57% | +5% | 15% | 20.4× | 18.8% | +14.5% |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 52.0× | 17.9% | +12.7% |
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 28% | 20.8× | 9.9% | +16.5% |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 16.3× | 2.2% | +19.7% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |